Iavi and moderna launch first-in-africa clinical trial of mrna hiv vaccine development program

Phase i trial in rwanda and south africa aims to evaluate mrna hiv vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity new york, ny and cambridge, ma / accesswire / may 18, 2022 / the nonprofit scientific research organization iavi and moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the first participant screenings are soon to start for a phase i clinical trial of an mrna hiv vaccine antigen (mrna-1644) at the center for family health research (cfhr) in kigali, rwanda, and the aurum institute in tembisa, south africa. the iavi-sponsored trial, iavi g003, builds on progress in hiv vaccine research.
MRNA Ratings Summary
MRNA Quant Ranking